Cargando…

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

Detalles Bibliográficos
Autores principales:	Miner, Jeffrey N., Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059967/ https://www.ncbi.nlm.nih.gov/pubmed/27733209 http://dx.doi.org/10.1186/s13075-016-1150-7

Ejemplares similares

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey, et al.
Publicado: (2016)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
por: Shen, Zancong, et al.
Publicado: (2015)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
por: Shen, Zancong, et al.
Publicado: (2016)

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Urate Handling in the Human Body
por: Hyndman, David, et al.
Publicado: (2016)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Patient considerations in the management of gout and role of combination treatment with lesinurad
por: Claus, Liza W, et al.
Publicado: (2018)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
por: Gillen, Michael, et al.
Publicado: (2016)

Lesinurad: A significant advancement or just another addition to existing therapies of gout?
por: Gupta, Ajay, et al.
Publicado: (2016)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad
por: Jones, Graeme, et al.
Publicado: (2017)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study
por: Shen, Zancong, et al.
Publicado: (2016)

Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
por: Singh, Jasvinder A., et al.
Publicado: (2015)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Publicado: (2017)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients
por: Ran, Zijing, et al.
Publicado: (2021)

Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARγM) in vitro
por: Heitel, Pascal, et al.
Publicado: (2018)

Lesinurad: what the nephrologist should know
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes
por: Guma, Monica, et al.
Publicado: (2022)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Uric Acid Accumulation in Gout
Publicado: (1903)

Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1
por: Cho, Sung Kweon, et al.
Publicado: (2015)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
por: Do, Hyunsue, et al.
Publicado: (2023)

Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
por: Uhlig, T., et al.
Publicado: (2022)

The development of an effective synthetic route of lesinurad (RDEA594)
por: Meng, Qing, et al.
Publicado: (2017)

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
por: Lee, You-Hyun, et al.
Publicado: (2006)

Treatment approaches and adherence to urate-lowering therapy for patients with gout
por: Aung, Thanda, et al.
Publicado: (2017)

Clinical Image: In vivo urate spherulites in a patient with gout
por: Pirker, Ian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_te8g86jrnq8491tu8gaf0eqc3o